Eli Lilly

Founded 1876
Founders Eli Lilly

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 39
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 37
Rounds per year 0.27
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.13
Exits 17
Key employees 4

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

Eli Lilly appeared to be the Corporate Investor, which was created in 1876. The main office of represented Corporate Investor is situated in the Indianapolis. The fund was located in North America if to be more exact in United States.

The common things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Eli Lilly performs on 0 percentage points less the average number of lead investments. The high activity for fund was in 2016. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies.

Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Eli Lilly, startups are often financed by Skyline Ventures, SV Health Investors, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Innovation, ARCH Venture Partners, Watson Fund. In the next rounds fund is usually obtained by RTW Investments LLC, Zesiger Capital, Unilever Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Immunocore, Perlegen Sciences, ImmunoGen. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Eli Lilly:
Typical Co-investors
Eli Lilly is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Eli Lilly:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
VICTORIA Venture Capital SCR-Pyme S.A. Spain, Barcelona
Modern Times Group (MTG) Sweden, Stockholm
Orca Capital China, Shanghai
Air Liquide Ventures France, Paris
Leitmotiv Private Equity China, Hong Kong Island
Allbrook & Company United States, Minneapolis
Mic Invest -
Rhon-Klinikum Germany, Bad Neustadt an der Saale
WDHB United States, Denver
OTS Japan, Kasugai
Wadi Makkah Ventures Saudi Arabia, Mecca
Ministry of Health Singapore Russia, Moscow
Startupbootcamp Scale San Francisco -
Teton Growth Partners United States, Jackson
SciClone Pharmaceuticals United States, Foster City
Los Angeles County Economic Development Corporation United States, Los Angeles
Alcumus Group United Kingdom, Cardiff
Capital6 Eagle -
Jozi Angels South Africa, Johannesburg
REMUS Capital United States, Boston

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Iterative Scopes

Computer Vision
Health Care
Health Diagnostics
Medical
1
$30M03 Aug 2021 Cambridge Massachusetts United States

MiNA Therapeutics

Biotechnology
Drug Discovery
Pharmaceutical
Pharmaceuticals
n/a
$15M06 Jul 2021 United Kingdom, London

TRex Bio

Bioinformatics
Biopharma
Biotechnology
1
$59M22 Jun 2021 California South San Francisco United States

DTx Pharma

Biotechnology
Therapeutics
1
$100M01 Mar 2021 California San Diego United States

Evox Therapeutics

Biotechnology
Health Care
Pharmaceutical
1
$94M18 Feb 2021 England Oxford United Kingdom

Auron Therapeutics

Biotechnology
Health Care
Therapeutics
1
$12M28 Jan 2021 Massachusetts United States

Blacksmith Medicines

Biotechnology
Genetics
Life Science
1
08 Jan 2021 California San Diego United States

Terns Pharmaceuticals

Biotechnology
Health Care
Medical
Medical Device
Pharmaceutical
1
$87M05 Jan 2021 California United States

Faze Medicines

Biotechnology
1
$81M10 Dec 2020 Cambridge Massachusetts United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Eli Lilly?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: